“Graves Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Disease Market.

The Graves Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Graves Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Graves Disease treatment therapies with a considerable amount of success over the years.

• Graves Disease companies working in the treatment market are TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others, are developing therapies for the Graves Disease treatment

• Emerging Graves Disease therapies in the different phases of clinical trials are- Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others are expected to have a significant impact on the Graves Disease market in the coming years.

• In May 2025, Amgen has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TEPEZZA® (teprotumumab) for marketing, making it the first authorized treatment specifically indicated for adult patients with moderate-to-severe Thyroid Eye Disease (TED).

• In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to advancing and commercializing potentially best-in-class therapies for serious and rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to veligrotug (“veli”), its lead anti-IGF-1R drug candidate for the treatment of thyroid eye disease (TED).

• In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing oral therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from the Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company’s lead oral small molecule candidate taken twice daily, targets the well-established IGF-1R pathway. It has demonstrated a favorable safety profile, having been tested in over 900 patients across 15 clinical trials for various conditions.

• In December 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to developing potentially best-in-class therapies for serious and rare conditions, has announced positive topline results from its Phase 3 THRIVE-2 clinical trial. The study evaluated veligrotug (veli), an intravenously administered anti-IGF-1R antibody, in patients with chronic thyroid eye disease (TED)—an autoimmune disorder marked by inflammation, tissue expansion, and damage around the eyes.

Graves Disease Overview

Graves’ disease is an autoimmune disorder that causes hyperthyroidism, which is the overproduction of thyroid hormones by the thyroid gland. It is characterized by the body’s immune system mistakenly attacking the thyroid gland, leading to excessive production of thyroid hormones. This condition can result in various symptoms, including weight loss, rapid heartbeat, sweating, nervousness, tremors, fatigue, heat intolerance, and protruding eyes (exophthalmos).

Get a Free Sample PDF Report to know more about Graves Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/graves-disease-pipeline-insight

Emerging Graves Disease Drugs Under Different Phases of Clinical Development Include:

• Research Program: TSHR Septerna

• Research Program: Cyclopeptides advanceCOR

• Research Program: EVOQ Therapeutics

• WP-1302: Worg Pharmaceuticals

• K1-70: AV7 Limited

• CFZ533: Novartis Pharmaceuticals

• Batoclimab: Immunovant Sciences GmbH

Graves Disease Route of Administration

Graves Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Graves Disease Molecule Type

Graves Disease Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Graves Disease Pipeline Therapeutics Assessment

• Graves Disease Assessment by Product Type

• Graves Disease By Stage and Product Type

• Graves Disease Assessment by Route of Administration

• Graves Disease By Stage and Route of Administration

• Graves Disease Assessment by Molecule Type

• Graves Disease by Stage and Molecule Type

DelveInsight’s Graves Disease Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Graves Disease product details are provided in the report. Download the Graves Disease pipeline report to learn more about the emerging Graves Disease therapies

Some of the key companies in the Graves Disease Therapeutics Market include:

Key companies developing therapies for Graves Disease are – Jubilant Pharma Holdings Inc., Novartis, Sun Pharma, Pfizer, F. Hoffmann-La Roche Ltd., Abbott, Thermo Fisher Scientific Inc., Institute of Isotopes Co. Ltd., bioMerieux SA, Horizon Therapeutics Ireland DAC, and others.

Graves Disease Pipeline Analysis:

The Graves Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Graves Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves Disease Treatment.

• Graves Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Graves Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Graves Disease drugs and therapies

Graves Disease Pipeline Market Drivers

• Increasing the prevalence of Graves Disease, increased public awareness about the treatment of Graves’ disease are some of the important factors that are fueling the Graves Disease Market.

Graves Disease Pipeline Market Barriers

• However, high cost of the treatment, complications associated with the treatment and other factors are creating obstacles in the Graves Disease Market growth.

Scope of Graves Disease Pipeline Drug Insight

• Coverage: Global

• Key Graves Disease Companies: TSHR Septerna, Cyclopeptides advanceCOR, EVOQ Therapeutics, Worg Pharmaceuticals, AV7 Limited, Novartis, Immunovant Sciences GmbH, and others

• Key Graves Disease Therapies: Research Program, WP-1302, K1-70, CFZ533, Batoclimab, and others

• Graves Disease Therapeutic Assessment: Graves Disease current marketed and Graves Disease emerging therapies

• Graves Disease Market Dynamics: Graves Disease market drivers and Graves Disease market barriers

Request for Sample PDF Report for Graves Disease Pipeline Assessment and clinical trials

Table of Contents

1. Graves Disease Report Introduction

2. Graves Disease Executive Summary

3. Graves Disease Overview

4. Graves Disease- Analytical Perspective In-depth Commercial Assessment

5. Graves Disease Pipeline Therapeutics

6. Graves Disease Late Stage Products (Phase II/III)

7. Graves Disease Mid Stage Products (Phase II)

8. Graves Disease Early Stage Products (Phase I)

9. Graves Disease Preclinical Stage Products

10. Graves Disease Therapeutics Assessment

11. Graves Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Graves Disease Key Companies

14. Graves Disease Key Products

15. Graves Disease Unmet Needs

16 . Graves Disease Market Drivers and Barriers

17. Graves Disease Future Perspectives and Conclusion

18. Graves Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/